期刊文献+

司库奇尤单抗治疗银屑病患者的疗效观察 被引量:1

Efficacy of Secukinumab in Patients with Psoriasis
下载PDF
导出
摘要 目的探讨司库奇尤单抗治疗银屑病患者的应用效果。方法选取该院2021年2月至2022年1月诊治的86例银屑病患者,按随机数字表法划分成两组,各43例。对照组给予复方丙酸氯倍他索软膏治疗,观察组则于此基础上加以司库奇尤单抗治疗,连续用药4周。对比两组临床疗效、炎性因子水平、皮肤屏障功能、皮损状态、生活质量、不良反应。结果观察组治疗总有效率高于对照组,有统计学差异(P<0.05);治疗前,两组白细胞介素-17(IL-17)、肿瘤坏死因子-α(TNF-α)、白细胞介素-23(IL-23)、皮质含量、角质层水分含量、经表皮水分丢失、银屑病面积与严重程度指数(PASI)与皮肤病生活质量指数(DLQI)评分相比,无统计学差异(P>0.05);治疗后,观察组IL-17、TNF-α、IL-23、经表皮水分丢失、PASI评分、DLQI评分均低于对照组,皮质含量、角质层水分含量均高于对照组,有统计学差异(P<0.05);两组不良反应相当,无统计学差异(P>0.05)。结论司库奇尤单抗治疗银屑病效果确切,可有效降低炎性因子水平,增强皮肤屏障功能,加快皮损修复,进而改善患者生活质量,且无严重不良反应,安全可靠。 Objective The authors investigate the effectiveness of secukinumab in patients with psoriasis.Methods The 86 psoriasis patients diagnosed from February 2021 to January 2022 were divided into two groups of 43 patients each.The control group was treated with compound clobetasol propionate ointment,and the observation group was treated with sekukizumab on this basis for 4 consecutive weeks continuously.Clinical efficacy,inflammatory factor levels,skin barrier function,skin lesion status,quality of life,and adverse effects were compared between the two groups.Results The total response rate of the observation group was higher than the control group,statistical difference(P<0.05);Pretherapy,two groups were compared with interleukin-17(IL-17),tumor necrosis factor-α(TNF-α),interleukin-23(IL-23),cortical content,cuticle water content,transepidermal water loss,psoriasis area and severity index(PASI)and dermatology quality of life index(DLQI)score,no statistical difference(P>0.05);Post-treatment,the observation group IL-17,TNF-α,IL-23,transepidermal water loss,PASI score,and DLQI score,were all lower than the control group.The cortical content and cuticle water content of the observation group were higher than the control group,statistical difference(P<0.05);There were no statistical difference between the both groups of adverse effects(P>0.05).Conclusion Secukinumab can effectively reduce the level of inflammatory factors,enhance the skin barrier function,accelerate the skin damage repair,and then improve the quality of life of patients,without serious adverse effects.It is safe and reliable.
作者 张秀钦 程波 方芳 ZHANG Xiuqin;CHEN Bo;FANG Fang(Department of Dermatological,Xiamen Haicang Hospital,Xiamen 361026,China;Department of Dermatological,the First Affiliated Hospital of Fujian Medical University,Fuzhou 350001,China)
出处 《中国医药指南》 2023年第15期83-85,共3页 Guide of China Medicine
关键词 银屑病 司库奇尤单抗 炎性因子 生活质量 不良反应 Psoriasis Secukinumab Inflammatory factors Quality of life Adverse reactions
  • 相关文献

参考文献12

二级参考文献58

共引文献168

同被引文献2

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部